Search

3 result(s) for 'author#Joohyuk Sohn' within BMC

1. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

   A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that th...

   Authors: Ji-Yeon Kim, Seri Park, Seock-Ah Im, Sung-Bae Kim, Joohyuk Sohn, Keun Seok Lee, Yee Soo Chae, Ki Hyeong Lee, Jee Hyun Kim, Young-Hyuck Im, Tae-Yong Kim, Kyung-Hun Lee, Jin-Hee Ahn, Gun Min Kim, In Hae Park, Soo Jung Lee…

   Citation: Cancer Communications 2019 39:29

   Content type: Original article Published on: 28 May 2019

   • View Full Text
   • View PDF

2. On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

   Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ca...

   Authors: Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joon Jeong and Joohyuk Sohn

   Citation: Breast Cancer Research 2023 25:4

   Content type: Research Published on: 12 January 2023

   • View Full Text
   • View PDF

3. S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

   This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer.

   Authors: Yong Wha Moon, Soohyeon Lee, Byeong-Woo Park, Eun-Kyung Kim, Seung Il Kim, Ja Seung Koo, Seho Park, Min Jung Kim, Hyun Cheol Chung, Joo-Hang Kim and Joohyuk Sohn

   Citation: BMC Cancer 2013 13:583

   Content type: Research article Published on: 6 December 2013

   • View Full Text
   • View PDF